EUVIMEDEUVIMED entdecken
FallberichtLeserbrief

Feasibility of multimodal therapy for rhabdomyosarcoma in a patient with Fukuyama congenital muscular dystrophy

Masanaka Sugiyama, Ayumu Arakawa, Shintaro Iwata, Kayoko Tao, Nami Shirakawa iD, Yuko Watanabe, Miho Nakajima, Akihiko Yoshida, Keiko Ishigaki, Akira Kawai, Chitose Ogawa

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31036 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Masanaka Sugiyama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Rhabdomyosarcoma. Die Arbeit nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

congenital muscular dystrophy (FCMD) is an autosomal recessive disorder caused by FKTN gene mutation, 1 which is involved in the glycosylation of α -dystroglycan. The main symptoms of FCMD are progressive muscle weakness and intellectual disability caused by brain anomalies. Respiratory failure, cardiac failure, and asphyxi-ation can be the main causes of mortality, and patients with FCMD have an average life expectancy of 20 years. FCMD is not considered as a tumor predisposition syndrome. Only few patients with FCMD develop malignancy. We present a patient with FCMD who developed spindle-cell/sclerosing-type rhabdomyosarcoma, managed with multimodal therapy without severe adverse events. A written informed consent was obtained from the patient’s guardian. A

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomaHumansWalker-Warburg SyndromeMaleCombined Modality TherapyFeasibility Studies

Autor:innen und Institutionen

  • Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Pediatrics, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.

ORCID-Profile: Nami Shirakawa

Zitieren

APA

Sugiyama, M., Arakawa, A., Iwata, S., Tao, K., Shirakawa, N., Watanabe, Y., Nakajima, M., Yoshida, A., Ishigaki, K., Kawai, A., & Ogawa, C. (2024). Feasibility of multimodal therapy for rhabdomyosarcoma in a patient with Fukuyama congenital muscular dystrophy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31036

Vancouver

Sugiyama M, Arakawa A, Iwata S, Tao K, Shirakawa N, Watanabe Y, et al. Feasibility of multimodal therapy for rhabdomyosarcoma in a patient with Fukuyama congenital muscular dystrophy. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31036

BibTeX
@article{Sugiyama2024,
  author = {Sugiyama, Masanaka and Arakawa, Ayumu and Iwata, Shintaro and Tao, Kayoko and Shirakawa, Nami and Watanabe, Yuko and Nakajima, Miho and Yoshida, Akihiko and Ishigaki, Keiko and Kawai, Akira and Ogawa, Chitose},
  title = {Feasibility of multimodal therapy for rhabdomyosarcoma in a patient with Fukuyama congenital muscular dystrophy},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31036}
}
Kostenlos starten →